10-K: 23andMe Faces Uncertain Future Amidst Bankruptcy, Nasdaq Delisting, and Asset Sale to Regeneron

23andMe Holding Co. has filed for Chapter 11 bankruptcy, delisted from Nasdaq, and is in the process of selling substantially all of its assets to Regeneron Pharmaceuticals, Inc. for $256 million, with a higher competing bid of $305 million from an affiliate of its co-founder.

Summary

• 23andMe Holding Co. and its subsidiaries filed for Chapter 11 bankruptcy on March 23, 2025, and are operating as debtors-in-possession.
• The company's Class A common stock was delisted from Nasdaq on March 31, 2025, and now trades on the OTC Pink Market under the symbol MEHCQ.
• An auction for substantially all of the company's assets concluded on May 16, 2025, with Regeneron Pharmaceuticals, Inc. selected as the successful bidder for $256.0 million in cash.
• Following the Regeneron bid, TTAM Research Institute, an affiliate of co-founder Anne Wojcicki, submitted a higher bid of $305.0 million, leading to an agreement for another bidding round starting at this price.
• The company secured a $35.0 million debtor-in-possession (DIP) credit facility with JMB Capital Partners Lending, LLC, which was later increased to $60.0 million on June 5, 2025, bearing a 14.0% interest rate and maturing on September 30, 2025.
• Total revenue decreased by 14% to $189.9 million for fiscal year 2025, down from $219.6 million in fiscal year 2024.
• Net loss from continuing operations improved by 59% to $(235.2) million in fiscal year 2025, compared to $(566.9) million in fiscal year 2024, largely due to the absence of a significant goodwill impairment charge seen in the prior year.
• Adjusted EBITDA from continuing operations slightly worsened, decreasing by 3% to $(93.3) million in fiscal year 2025 from $(90.9) million in fiscal year 2024.
• The Therapeutics operating segment was discontinued in November 2024, ceasing additional investment in its two clinical trials, leading to a 54% decrease in net loss from discontinued operations to $(45.7) million.
• The company's PGS customer base decreased by approximately 5% from 15.1 million on March 31, 2024, to 14.4 million on March 31, 2025, and further to 14.0 million by May 31, 2025.
• Settlements totaling $37.5 million were reached for class action and arbitration claims related to the October 2023 cyber incident, with $39.1 million accrued as liabilities offset by $18.1 million in probable insurance recoveries.
• The company abandoned its South San Francisco lab facility in December 2024 and its Sunnyvale facility in March 2025, incurring significant lease abandonment and impairment charges totaling $50.5 million for Sunnyvale and $10.0 million for South San Francisco.

Sentiment

Score: 1

Explanation: The company is in Chapter 11 bankruptcy, has been delisted from Nasdaq, and is selling substantially all of its assets. This indicates a severe and potentially terminal financial situation for existing shareholders, despite efforts to restructure and sell assets.

Positives

• Net loss from continuing operations significantly improved by 59% in fiscal year 2025, primarily due to the absence of the large goodwill impairment charge recorded in fiscal year 2024.
• The company successfully regained compliance with Nasdaq's minimum bid price and corporate governance requirements prior to its delisting, demonstrating efforts to meet listing standards.
• Settlements for the cyber incident claims have been reached for U.S. customers, providing a path to resolve significant litigation, with a portion of costs offset by probable insurance recoveries.
• The strategic decision to discontinue the Therapeutics segment and focus on core consumer and research services is intended to reduce operating costs and align with current strategy, leading to a significant reduction in net loss from discontinued operations.

Negatives

• The company filed for Chapter 11 bankruptcy, indicating severe financial distress and raising substantial doubt about its ability to continue as a going concern.
• The Class A common stock was delisted from Nasdaq and now trades on the less liquid OTC Pink Market, significantly impacting stock liquidity and investor access.
• Total revenue declined by 14% in fiscal year 2025, driven by decreases in PGS kit sales volume and telehealth services revenue.
• The PGS customer base experienced a notable decline, decreasing by 5% year-over-year and continuing to fall post-fiscal year end, indicating potential erosion of the core business.
• Adjusted EBITDA from continuing operations slightly worsened, reflecting ongoing operational losses despite cost-cutting measures.
• The company incurred substantial expenses related to the bankruptcy proceedings, cyber incident litigation, and facility abandonments, totaling tens of millions of dollars.
• The company's accumulated deficit reached $2.5 billion as of March 31, 2025, highlighting significant historical losses.
• The DIP facility carries a high interest rate of 14.0%, increasing financing costs during bankruptcy proceedings.
• The potential sale of substantially all assets, including core business components, indicates a significant reduction in the company's operational scope and future prospects as a standalone entity.

Risks

• The company is subject to significant risks and uncertainties associated with its Chapter 11 Cases, including the ability to successfully consummate the asset sale or reorganize/liquidate, high bankruptcy costs, and potential adverse effects on business relationships.
• There is a significant risk that holders of common stock may receive little to no recovery under the Chapter 11 Cases, and the stock may become worthless.
• The delisting from Nasdaq has adversely affected the liquidity of the Class A common stock, making it more difficult for investors to trade shares and negatively impacting access to equity markets.
• Financial results are expected to be volatile during the Chapter 11 Cases due to restructuring activities, contract terminations, and claims assessments, making historical performance not indicative of future results.
• Delays in the Chapter 11 Cases increase the risk of being unable to sell assets or reorganize/liquidate, and further increase bankruptcy costs.
• The DIP Facility has substantial restrictions and covenants, and non-compliance could materially adversely impact financial condition, operating results, and cash flows.
• Long-term liquidity requirements and adequacy of capital resources are difficult to predict, with no assurance that current cash and DIP facility funds will be sufficient to fund operations through emergence from Chapter 11.
• Matters related to Chapter 11 Cases consume substantial management time and attention, potentially adversely affecting business operations and leading to increased employee attrition.
• The company may not be able to obtain confirmation of a Chapter 11 plan of reorganization or liquidation, or complete any Bankruptcy Court-approved sales, including the current transaction with Regeneron/TTAM.
• Conversion of the Chapter 11 case to Chapter 7 liquidation is a risk, in which case common stock would likely be worthless.
• The Chapter 11 Cases and covenants in the Asset Purchase Agreement limit management's flexibility in running the business.
• The market for personal genetics products and services has experienced a recent overall decline, which could continue to adversely affect business and results of operations.
• Reliance on key sole suppliers for manufacturing and services for PGS kits poses a risk to meeting customer demand if supply chain issues arise.
• The business relies on the continual growth of its customer research database; a decline in consenting customers or data deletions could adversely affect research services revenue and database effectiveness.
• Media reports on consumer data privacy and security concerns, including the cyber incident and potential data transfer to a new buyer, may decrease demand and lead to further customer data deletions.
• The company faces legal, reputational, and financial risks if it fails to protect customer and patient data from security breaches or cyberattacks, as evidenced by the recent criminal cyber incident.
• Economic uncertainty or downturns, particularly affecting discretionary consumer spending, could adversely affect business, financial condition, and results of operations.
• Impairment in the value of intangible assets could have a material adverse effect on operating results and financial condition.
• Strategic restructurings and headcount reductions have significantly changed the business, resulted in substantial expenses, and may not yield anticipated savings or could disrupt operations further.
• Extensive regulation by federal and state agencies, and equivalent foreign agencies, could result in unanticipated expenses or limit the ability to offer products and services.
• Changes in patent law or interpretations could diminish the value of patents, impairing the ability to protect products and services.
• The dual-class stock structure may limit stockholders' ability to influence important decisions.

Future Outlook

The company's future is highly uncertain and contingent on the successful implementation of a Chapter 11 plan of reorganization, which includes the sale of substantially all of its assets. If the transaction with Regeneron (or the competing TTAM bid) is consummated, the company expects to cease operating as a going concern. The telehealth services business (Lemonaid Health) is expected to be wound down following the asset sale. The company anticipates incurring material reorganization expenses in the near term and continues to face substantial doubt about its ability to continue as a going concern.

Management Comments

• Management continues to believe there is substantial doubt about our ability to continue as a going concern within one year after the date of issuance of the consolidated financial statements.
• The November 2024 Reduction Plan was intended to restructure and strategically align our workforce and organization with our current strategy, and to reduce operating costs.
• Operating results have been and continue to be negatively impacted as a result of the Chapter 11 Cases, including decreases in revenue and number of the PGS customers.
• The company's ability to continue as a going concern is contingent upon, among other things, its ability to, subject to the Bankruptcy Court's approval, successfully emerge from the Chapter 11 Cases and generate sufficient liquidity from the restructuring to meet our obligations and operating needs.

Industry Context

The document highlights a challenging environment for direct-to-consumer genetic testing, noting a recent overall decline in the market for personal genetics products and services. The telehealth market is described as maturing and volatile, with increasing competition from new entrants and traditional healthcare providers. The company's discontinuation of its Therapeutics segment reflects a broader trend of biotech companies re-evaluating costly drug development programs, especially in a tight capital market. The reliance on large genetic databases for research services remains a key strategy, but competition from public biobanks and AI-driven approaches is noted. Regulatory scrutiny, particularly from the FDA regarding laboratory-developed tests (LDTs) and data privacy laws, continues to shape the industry landscape.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects for direct financial or operational benchmarking against industry standards. However, it notes that 23andMe was the first company to obtain FDA authorization for a direct-to-consumer genetic test and is the only company with FDA authorization, clearance, or exemption for all its carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports, suggesting a leading position in regulatory compliance for its core PGS offerings compared to competitors who may not fully comply with FDA regulations.
• The company's reliance on a single supplier for saliva collection kits and a single laboratory service provider for customer sample processing is identified as a concentration risk, which may be higher than industry best practices for supply chain diversification.
• The significant decline in PGS customer base and overall revenue, coupled with the Chapter 11 filing, indicates performance well below industry growth or stability standards for established consumer health companies, particularly in the direct-to-consumer space.
• The high 14.0% interest rate on the DIP Facility is indicative of the distressed financial situation, likely higher than typical borrowing costs for healthy companies in the biotechnology or healthcare sectors.

Management Changes

Corporate Governance

Legal Proceedings

• The company and certain subsidiaries filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code on March 23, 2025, which has stayed substantially all proceedings pending against the company.
• Multiple class action claims were filed against the company in federal and state courts, as well as arbitration claims, related to the October 2023 cyber incident.
• On March 21, 2025, the company entered into settlements for the cyber incident claims with arbitration claimants and state court plaintiffs, agreeing to pay an aggregate of $37.5 million to settle claims brought on behalf of U.S. customers (who do not opt out).
• The settlements related to the cyber incident are classified as liabilities subject to compromise and will be subject to claims resolution in the Bankruptcy Court.
• The company is responding to inquiries from various governmental officials and agencies regarding the cyber incident.

Related Party Transactions

• GlaxoSmithKline (GSK) is considered a related party, holding a 21.7% voting interest as of March 31, 2025. The company had a collaboration agreement with GSK, which included a non-exclusive license to new data for a $20.0 million fee, recognized in fiscal 2025.
• The Troper Wojcicki Foundation (TWF), affiliated with Anne Wojcicki (co-founder, former CEO, and current board member), entered into a research services agreement with the company in January 2024 for $5.4 million over five years.
• TTAM Research Institute, a California nonprofit public benefit corporation and an affiliate of Anne Wojcicki, was selected as the next-highest or otherwise second-best bidder for substantially all of the company's assets in the bankruptcy auction, with a bid of $305.0 million.

Stakeholder Impact

• **Shareholders**: Face substantial doubt about the company's ability to continue as a going concern, with a significant risk that common stock may become worthless due to bankruptcy proceedings and the asset sale. Delisting from Nasdaq has severely impacted liquidity.
• **Employees**: Experienced significant headcount reductions (40% of workforce in November 2024) and face uncertainty due to the Chapter 11 Cases, which may lead to increased attrition. Management's attention is diverted to bankruptcy matters.
• **Customers**: PGS customers have decreased, potentially due to the cyber incident and negative media coverage. The planned wind-down of the telehealth services business (Lemonaid Health) will impact customers relying on those services. Data privacy and security concerns remain a key issue.
• **Suppliers/Vendors**: The company is seeking approval to reject numerous contracts, including real estate leases, which impacts landlords and other vendors. The bankruptcy process may affect relationships with vendors and suppliers.
• **Creditors**: The Chapter 11 Cases are designed to address creditor claims, with liabilities subject to compromise. The outcome of the asset sale will determine the proceeds available for distribution to creditors, with senior claims (like the DIP Facility) having priority.

Next Steps

• Bankruptcy Court hearing scheduled for June 17, 2025, to consider approval of the Asset Purchase Agreement with Regeneron.
• If the Regeneron transaction is not consummated, the Debtors will seek Bankruptcy Court authorization to consummate the transactions contemplated by the bid of TTAM Research Institute.
• The company has agreed to wind-down its telehealth services business (Lemonaid Health, Inc.) as promptly as reasonably practicable following the closing date of the asset sale.
• The license to new data under the 2023 GSK Amendment will expire on October 28, 2025.
• The DIP Facility has a scheduled maturity date of September 30, 2025.
• The company expects to settle AIP annual incentive bonuses of approximately $5.3 million in cash in fiscal 2026.
• The company will continue to incur significant expenses in connection with the Chapter 11 Cases.

Key Dates

Recommendation

Keywords

Genetic Testing, Direct-to-Consumer Genetics, Telehealth, Genomic Research, Biotechnology, Bankruptcy, Chapter 11, Asset Sale, Regeneron Pharmaceuticals, Nasdaq Delisting, DIP Financing, Cybersecurity Incident, Personal Genome Service, Lemonaid Health, Precision Health, Data Privacy, FDA Authorization, Clinical Trials, Corporate Restructuring